Willow Biosciences Inc. announced a collaboration with a biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs). Willow's collaboration partner recognized the need to employ more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste and sought Willow's expertise in developing and scaling key ingredients. The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale.

The development phase of this funded collaboration is expected to last approximately two months. Due to the competitive nature of the targeted ingredient applications, the partner's name and further information is not being disclosed at this time. This agreement represents the 5th new development agreement executed by Willow in 2023, with a robust pipeline of other potential collaborations in process.